- Programme
- Thursday
DAY 2 — THURSDAY 2ND JULY 2026
Day 2
Thursday
2nd July 2026
DAY 2 — THURSDAY 2ND JULY 2026
8:00–9:00
Welcome back & coffee
8:15–8:45
Breakfast with the Expert – Sponsored Breakout Sessions
See dedicated Breakout Sessions section ↓
JOURNAL CLUB — CRITICAL READING OF RECENT KEY PUBLICATIONS
Chair: Massi di Pietro
9:00–10:00
This interactive session will take a deep dive into a selection of recent high-impact studies shaping the diagnosis, surveillance, and treatment of Barrett's oesophagus and early neoplasia.
9:00–9:15
Biomarker risk stratification to make surveillance work: Deconstructing the NHS Pilot and DELTA Trial.
Nastazja Pilonis
9:15–9:30
Endoscopy surveillance for Barrett's Oesophagus under the spotlight: Deconstructing the BOSS Trial.
Helen Coleman
9:30–9:45
Endoscopic treatment for high-Risk T1a and T1b Adenocarcinoma: Deconstructing the CONGRESS Trial.
Roos Pouw
9:45–10:00
Q&A
10:00–10:30
coffee break & networking
BARRETT'S SURVEILLANCE DEBATE: ABANDON OR EVOLVE?
Chair: Helen Coleman
10:30–10:45
End surveillance now: The evidence says enough.
Massi di Pietro
10:45–11:00
Switch It Up: Making surveillance work with non-endoscopy tools.
Vani Konda
11:00–11:15
Discussion
UPPER GI THERAPEUTIC ENDOSCOPY. PRACTICAL IMAGE & VIDEO SESSION
Chair: Wouter Nagengast & Henna Söderström
11:15–11:30
How to perform an Oesophageal EMR. Tips & Tricks and how to avoid mistakes.
Nastazja Pilonis
11:30–11:45
Principles and strategies on how to perform an Upper GI ESD. Tips & Tricks and how to avoid mistakes.
Mo Abdelrahim
11:45–12:00
Decoding EMR/ESD histopathology reports: A guide for endoscopists.
Sindhu Menon
12:00–12:15
Q&A
BARRETT'S TREATMENT DEBATE: SHOULD ESD REPLACE EMR FOR EARLY NEOPLASIA RESECTION?
Chair: Roos Pouw
12:15–12:30
Yes - Go Big or Go Home: Why ESD should replace EMR.
Alanna Ebigbo
12:30–12:45
No - EMR Endures: proven, practical, and here to stay.
Julia Gauci
12:45–13:00
Discussion
13:00–14:00
lunch break & networking
SOME OF THE CURRENT CONTROVERSIES IN BARRETT'S ENDOTHERAPY
Chair: Vani Konda & Mário Dinis-Ribeiro
14:00–14:15
The risk of overtreatment in Barrett's Endotherapy: Often less is more – Knowing when to hold back may be the best clinical decision.
Wouter Nagengast
14:15–14:30
Low Grade Dysplasia (LGD) in the real world beyond the SURF Trial: True Dysplasia or Overdiagnosis? Ablation or Follow up?
Massi di Pietro
14:30–14:45
Pushing the boundaries: endoscopic management of pT1b adenocarcinoma - Is there still a role for surgery?
Henna Söderström
14:45–15:00
NICE Guidelines recommend considering radiotherapy with/without chemotherapy for high risk T1b oesophageal adenocarcinoma after EMR/ESD – Supporting evidence and current real-world practice.
Eleanor James
15:00–15:15
Q&A
BARRETT'S POST-ENDOTHERAPY FOLLOW-UP DEBATE
Chair: Leo Alexandre
15:15–15:30
Yes - Time to let go: Discharge after proven success. And I'll tell you when.
Mário Dinis-Ribeiro
15:30–15:45
No - Don't drop the guard: Follow-up should continue. And I'll tell you how.
Elizabeth Ratcliffe
15:45–16:00
Discussion
16:00–16:30
tea break & networking
UGI MDT PANEL REAL CASE DISCUSSIONS
UGI MDT Chair: James Catton
16:30–17:30
UGI MDT Panel — Mário Dinis-Ribeiro, Yutaro Higashi, Eleanor James, Sindhu Menon, Massi di Pietro, Yuto Shimamura and Henna Söderström